Tocriscreen 2.0 Max

Pricing Availability   Qty
说明: Bioactive compound library for high-throughput screening, high-content screening, target validation and assay development; comprised of 1280 biologically active compounds (250 μL 10 mM DMSO solutions)
说明书
引用文献 (22)
评论
文献 (1)

生物活性 for Tocriscreen 2.0 Max

Tocriscreen 2.0 Max is a library of 1280 biologically active compounds from the Tocris catalog. Covers a wide range of pharmacological targets and research areas. Compounds are supplied pre-dissolved in 250 μL 10 mM DMSO solutions. A smaller volume is available as Tocriscreen 2.0 Mini (Cat. No. 7151) and Tocriscreen 2.0 Micro (Cat. No. 7152).

This library replaces the Tocriscreen Plus (Cat. No. 5840).

For more information on the Tocriscreen 2.0 Compound Libraries, please download our informative flyer.

If this library does not suit your needs, please submit your requirements through our Tocriscreen PRO custom compound library service.

Key Format and Product Details for Tocriscreen 2.0 Max

  • 96-well racks with Matrix storage tubes & SepraSeal caps
  • Compounds arranged 80 per rack with 16 racks per library
  • Pre-dissolved in DMSO
  • Many compounds are exclusive to Tocris
  • Unique library with low overlap
  • Full chemical and biological data available
  • Exceptional purity
Target Classes Covered by the Tocriscreen 2.0 Compound Library

The Tocriscreen 2.0 Compound Library contains bioactive compounds covering a diverse range of molecular targets; 7-TM receptors (GPCRs; 27%), non-kinase enzymes (21%), kinases including enzyme-linked receptors (20%), ion channels (13%), cell biology targets (9%), nuclear receptors (6%), and transporters and other pharmacological targets (5%).

索取化合物列表

如需索取 Tocriscreen 2.0 Max 中包含的化合物列表,请点击下方的索取图块。化合物列表以 Excel 或 SD 格式提供。

索取化合物列表: Tocriscreen 2.0 Max

技术数据 for Tocriscreen 2.0 Max

储存 Store at -20°C

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for Tocriscreen 2.0 Max

分析证书目前不在网上提供。
请联系客户服务

参考文献 for Tocriscreen 2.0 Max

参考文献是支持产品生物活性的出版物。

Li et al (2011) Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Research 21 196 PMID: 20956998

Beacham et al (2010) Cell-based potassium ion channel screening using the FluxORTM assay. J.Biomol.Screen. 15 44 PMID: 20208034

Hattori et al (2010) Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. Proc.Natl.Acad.Sci.USA 107 3546 PMID: 20142487

Li et al (2015) Small-molecule-driven direct reprogramming of mouse fibroblasts into functional neurons. Cell Stem Cell 17 195 PMID: 26253201

Yu et al (2015) Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16 142 PMID: 25658371


If you know of a relevant reference for Tocriscreen 2.0 Max, please let us know.

按标靶查看相关产品

关键词: Tocriscreen 2.0 Max, Tocriscreen 2.0 Max supplier, biologically, active, pre-dissolved, DMSO, 250ul, 10mM, solutions, Tocriscreen, Compound, Collections, Screening, Library, Libraries, HTS, HCS, high, throughput, content, 7150, Tocris Bioscience

22 篇 Tocriscreen 2.0 Max 的引用文献

引用文献是使用了 Tocris 产品的出版物。 Tocriscreen 2.0 Max 的部分引用包括:

Sasame et al (2022) HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E-mutant high-grade glioma. Clin.Cancer Res. 28 2425 PMID: 35344043

Gull et al (2022) Screening of chemical libraries using xenopus embryos and tadpoles for phenotypic drug discovery. Cold Spring Harb.Protoc. PMID: 36180216

Gruber et al (2022) Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform. Hum.Reprod. deac007 PMID: 35048946

Sichler et al (2024) Screening for new ligands of the MB327-PAM-1 binding site of the nicotinic acetylcholine receptor. Toxicol.Letter. 394 23 PMID: 38387764

Li et al (2023) High-throughput screening for myelination promoting compounds using human stem cell-derived oligodendrocyte progenitor cells. iScience 26 106156 PMID: 36852281

Galarion et al (2023) An extensively validated whole-cell biosensor for specific, sensitive and high-throughput detection of antibacterial inhibitors targeting cell-wall biosynthesis. J.Antimicrob.Chemother. 78 646 PMID: 36626387

Honfozo et al (2023) An image-based high-content screening for compounds targeting Toxoplasma gondii repurposed inhibitors effective against the malaria parasite Plasmodium falciparum. Front.Cell.Infect.Microbiol. 13 1102551 PMID: 36936758

Xie et al (2020) High-throughput screening identified mitoxantrone to induce death of hepatocellular carcinoma cells with autophagy involvement. Biochem.Biophys.Res.Commun. 521 232 PMID: 31653348

Lake et al (2020) Drug and siRNA screens identify ROCK2 as a therapeutic target for ciliopathies. BioRXiv

Telpoukhovskaia et al (2020) Discovery of small molecules that normalize the transcriptome and enhance cysteine cathepsin activity in progranulin-deficient microglia. Science Reports 10 13688 PMID: 32792571

Tian et al (2020) Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists. J Med Chem 63 6164 PMID: 32345019

Tanaka et al (2021) Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody. Sci Rep 11 1712 PMID: 33462327

Endersby et al (2021) Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. Sci Transl Med 13 eaba7401 PMID: 33472956

Ehteda et al (2021) Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep 35 108994 PMID: 33852836

Chen et al (2021) A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells Nat.Methods 18 528 PMID: 33941937

Yang et al (2017) Derivation of Pluripotent Stem Cells with In Vivo Embryonic and Extraembryonic Potency. Cell 169 243 PMID: 28388409

Trogden et al (2018) An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. FASEB J. 32 2841 PMID: 29401610

Diamantopoulou et al (2019) Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant. Elife 8 e44889 PMID: 31180326

Gabriel et al (2019) A library screening strategy combining the concepts of MS binding assays and affinity selection mass spectrometry. Front Chem 7 665 PMID: 31637233

Danthi et al (2019) Identification and Characterization of Inhibitors of a Neutral Amino Acid Transporter, SLC6A19, Using Two Functional Cell-Based Assays. SLAS Discov 24 111 PMID: 30589598

Dittmar et al (2016) Drug Repurposing Screening Identifies Novel Compounds That Effectively Inhibit Toxoplasma gondii Growth. mSphere 1 e00042 PMID: 27303726

Fukuda et al (2016) Tubulin is a molecular target of the Wnt-activating chemical probe. BMC Biochemistry 17 9 PMID: 27207629


您是否知道使用了 Tocris Tocriscreen 2.0 Max 的优秀论文? 请告知我们.

Tocriscreen 2.0 Max 的评论

目前没有该产品的评论。 Be the first to review Tocriscreen 2.0 Max and earn rewards!

Have you used Tocriscreen 2.0 Max?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Tocriscreen Compound Libraries

Tocriscreen Compound Libraries

This brochure gives an overview of the unique TocriscreenTM bioactive compound library range, including

  • Tocriscreen 2.0 Compound Library
  • Focused Tocriscreen Libraries
  • Tocriscreen FDA-approved Drug Library
  • Tocriscreen PRO Custom Service